Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Cancer cells hijack T-cell mitochondria

Nanotube-mediated acquisition of immune cells’ mitochondria by tumour cells is a novel mechanism for immune evasion that can be pharmacologically targeted to potentiate cancer immunotherapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Pharmacological blockade of mitochondrial hijacking improves T-cell antitumour immunity.


  1. Saha, T. et al. Nat. Nanotechnol. (2021).

  2. Bantug, G. R. et al. Nat. Rev. Immunol. 18, 19–34 (2018).

    Article  CAS  Google Scholar 

  3. Sukumar, M. et al. Cell Metab. 23, 63–76 (2016).

    Article  CAS  Google Scholar 

  4. Spees, J. L. et al. Proc. Natl Acad. Sci. USA 103, 1283–1288 (2006).

    Article  CAS  Google Scholar 

  5. Berridge, M. et al. Anal. Biochem. 552, 75–80 (2018).

    Article  CAS  Google Scholar 

  6. Mohammadalipour, A. et al. Front. Cell Dev. Biol. 8, 1519 (2020).

    Article  Google Scholar 

  7. Burt, R. et al. Blood 134, 1415–1429 (2019).

    Article  CAS  Google Scholar 

  8. Moschoi, R. et al. Blood 128, 253–264 (2016).

    Article  CAS  Google Scholar 

  9. Yu, Y.-R. et al. Nat. Immunol. 21, 1540–1551 (2020).

    Article  CAS  Google Scholar 

  10. Pilipow, K. et al. JCI Insight 3, e122299 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Luca Gattinoni.

Ethics declarations

Competing interests

L.G. has consulting agreements with Lyell Immunopharma, AstraZeneca, Turnstone Biologics, Xcelcyte. L.G. is on the scientific advisory board of Poseida Therapeutics and Kiromic, and a stockholder of Poseida Therapeutics. J.G.B. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baldwin, J.G., Gattinoni, L. Cancer cells hijack T-cell mitochondria. Nat. Nanotechnol. 17, 3–4 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Find nanotechnology articles, nanomaterial data and patents all in one place. Visit Nano by Nature Research